Founded in 2009, 22nd Century Group, LLC is a pioneering agricultural biotechnology company dedicated to enhancing health and wellness through advanced plant science. Initially established as a wholesaler of electronic parts and communications equipment, the company has since pivoted to focus on cigarette harm reduction and other health-related plant-based innovations. Their core mission is to leverage biotechnology to create healthier alternatives in the tobacco industry and beyond, targeting markets that prioritize wellness and sustainability.

Notable figures affiliated with 22nd Century Group include its leadership team and board of directors, who bring extensive experience in biotechnology and business strategy. The company has achieved significant milestones, including being listed on Nasdaq under the ticker symbol XXII. Their impact is marked by their innovative approach to reducing the harmful effects of smoking through genetically engineered tobacco plants, positioning them as a key player in the health-focused biotech sector.